Search Results for "treatment guidelines"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for treatment guidelines. Results 391 to 400 of 432 total matches.
Two Drugs for Advanced HER2-Positive Breast Cancer (Enhertu and Tukysa)
The Medical Letter on Drugs and Therapeutics • Nov 16, 2020 (Issue 1611)
for treatment of previously-treated unresectable or metastatic human epidermal growth factor receptor 2 (HER2 ...
The FDA has approved two new drugs for treatment
of previously-treated unresectable or metastatic
human epidermal growth factor receptor 2 (HER2)-positive breast cancer: fam-trastuzumab deruxtecannxki
(Enhertu – Daiichi-Sankyo/AstraZeneca), an IV
HER2-directed monoclonal antibody linked to the
topoisomerase I inhibitor DXd, and tucatinib (Tukysa – Seagen), an oral tyrosine kinase inhibitor.
Tenapanor (Ibsrela) for Irritable Bowel Syndrome with Constipation
The Medical Letter on Drugs and Therapeutics • Jun 13, 2022 (Issue 1652)
(Ibsrela - Ardelyx),
a sodium/hydrogen exchanger 3 (NHE3) inhibitor, for
twice-daily oral treatment ...
The FDA has approved tenapanor (Ibsrela - Ardelyx),
a sodium/hydrogen exchanger 3 (NHE3) inhibitor, for
twice-daily oral treatment of irritable bowel syndrome
with constipation (IBS-C) in adults. Tenapanor is the
first NHE3 inhibitor to become available in the US.
Ceftolozane/Tazobactam (Zerbaxa) - A New Intravenous Antibiotic
The Medical Letter on Drugs and Therapeutics • Mar 02, 2015 (Issue 1463)
, for
intravenous treatment of complicated urinary tract
and intra- abdominal infections in adults.
Pronunciation ...
The FDA has approved ceftolozane/tazobactam
(Zerbaxa – Cubist), a combination of a new cephalosporin
antibiotic and a beta-lactamase inhibitor, for
intravenous treatment of complicated urinary tract
and intra-abdominal infections in adults.
Retapamulin (Altabax) - A New Topical Antibiotic
The Medical Letter on Drugs and Therapeutics • Feb 25, 2008 (Issue 1280)
; Altabax – GlaxoSmithKline) is a topical antibiotic recently approved by
the FDA for treatment of bullous ...
Retapamulin (re-tap'-a-mue'-lin; Altabax - Glaxo SmithKline) is a topical antibiotic recently approved by the FDA for treatment of bullous and non-bullous impetigo due to Streptococcus pyogenes and methicillin-susceptible Staphylococcus aureus. It is available as a 1% ointment by prescription only.
Sotatercept (Winrevair) for Pulmonary Arterial Hypertension
The Medical Letter on Drugs and Therapeutics • May 13, 2024 (Issue 1702)
:1524.
2. M Humbert et al. 2022 ESC/ERS guidelines for the diagnosis and
treatment of pulmonary ...
The FDA has approved sotatercept-csrk (Winrevair –
Merck), a first-in-class activin signaling inhibitor, to
increase exercise capacity, improve WHO functional
class, and reduce the risk of clinical worsening
events in adults with WHO Group 1 pulmonary arterial
hypertension (PAH).
Med Lett Drugs Ther. 2024 May 13;66(1702):73-5 doi:10.58347/tml.2024.1702a | Show Introduction Hide Introduction
Byvalson - A Beta Blocker/ARB Combination for Hypertension
The Medical Letter on Drugs and Therapeutics • Sep 12, 2016 (Issue 1503)
blocker (ARB)
valsartan (Diovan, and generics), for treatment of
hypertension. It is the only ...
The FDA has approved Byvalson (Allergan), a fixed-dose
combination of the beta blocker nebivolol
(Bystolic) and the angiotensin receptor blocker (ARB)
valsartan (Diovan, and generics), for treatment of
hypertension. It is the only combination product that
contains nebivolol, and the first to combine a beta
blocker with an ARB.
Atazanavir (Reyataz) and Emtricitabine (Emtriva) for HIV Infection
The Medical Letter on Drugs and Therapeutics • Nov 10, 2003 (Issue 1169)
by the FDA for treatment of HIV-1 infection. Both are
taken once daily, unlike most anti-HIV drugs ...
Atazanavir (Reyataz - Bristol-Myers Squibb), a new protease inhibitor (PI), and emtricitabine (Emtriva - Gilead), a nucleoside analogue reverse transcriptase inhibitor (NRTI) chemically similar to lamivudine, have been approved by the FDA for treatment of HIV-1 infection. Both are taken once daily, unlike most anti-HIV drugs.
Nemolizumab (Nemluvio) for Atopic Dermatitis
The Medical Letter on Drugs and Therapeutics • Feb 17, 2025 (Issue 1722)
for treatment of moderate
to severe atopic dermatitis in patients ≥12 years
old whose disease ...
Nemolizumab (Nemluvio – Galderma), a subcutaneously
injected interleukin-31 (IL-31) receptor
antagonist, has been approved by the FDA for use
in combination with topical corticosteroids and/or calcineurin inhibitors for treatment of moderate
to severe atopic dermatitis in patients ≥12 years
old whose disease is not adequately controlled with
topical prescription drugs. It is the first IL-31 receptor
antagonist to be approved in the US for this indication.
Nemolizumab was approved earlier for treatment of
prurigo nodularis in adults.
Med Lett Drugs Ther. 2025 Feb 17;67(1722):25-7 doi:10.58347/tml.2025.1722a | Show Introduction Hide Introduction
Two New Oral Testosterone Products for Hypogonadism
The Medical Letter on Drugs and Therapeutics • Oct 31, 2022 (Issue 1662)
of testosterone undecanoate — Kyzatrex (Marius)
and Tlando (Antares) — for treatment of males
with a deficiency ...
The FDA has approved two new oral formulations
of testosterone undecanoate — Kyzatrex (Marius)
and Tlando (Antares) — for treatment of males
with a deficiency of endogenous testosterone
due to conditions such as Klinefelter syndrome,
orchiectomy, toxic damage from chemotherapy or
alcohol, or pituitary-hypothalamic injury caused
by tumors, trauma, or radiation. Jatenzo, another
oral testosterone undecanoate formulation, was
approved for the same indication in 2019. No
testosterone products are approved for treatment of
low testosterone levels due solely to...
Drugs for Bipolar Disorder
The Medical Letter on Drugs and Therapeutics • Apr 01, 2024 (Issue 1699)
Treatments (CANMAT) and International Society for Bipolar
Disorders (ISBD) 2018 guidelines ...
Bipolar disorder is characterized by episodes of
mania, hypomania, and depression. Recurrences of
manic or (more frequently) depressive symptoms
are common. About 15-20% of patients with bipolar
disorder die by suicide.
Med Lett Drugs Ther. 2024 Apr 1;66(1699):49-54 doi:10.58347/tml.2024.1699a | Show Introduction Hide Introduction